Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. 6-chloro-1,3,4,9-tetrahydro-1-(4-methoxyphenyl)-, 4-chlorophenyl Ester, (1s)-2h-pyrido(3,4-b)indole-2-carboxylic Acid
2. Emvododstat
3. Ptc299
1. Emvododstat
2. Ptc299
3. Ptc-299
4. 1256565-36-2
5. Emvododstat [usan]
6. 053qd2i96a
7. Emvododstat [inn]
8. Emvododstat [who-dd]
9. Schembl8509210
10. Chembl4650336
11. Gtpl11421
12. 1219951-09-3
13. 2h-pyrido(3,4-b)indole-2-carboxylic Acid, 6-chloro-1,3,4,9-tetrahydro-1-(4-methoxyphenyl)-, 4-chlorophenyl Ester, (1s)-
14. Ex-a5798
15. At24059
16. Hy-124593
17. Cs-0087039
18. 4-chlorophenyl (1s)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydro-2h-pyrido(3,4-b)indole-2-carboxylate
19. 4-chlorophenyl (s)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indole-2-carboxylate
| Molecular Weight | 467.3 g/mol |
|---|---|
| Molecular Formula | C25H20Cl2N2O3 |
| XLogP3 | 6.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 4 |
| Exact Mass | 466.0850979 g/mol |
| Monoisotopic Mass | 466.0850979 g/mol |
| Topological Polar Surface Area | 54.6 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 651 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
PTC299 demonstrated a broad range of activity in blocking VEGF synthesis in multiple tumor types, including breast, cervical, colorectal, fibrosarcoma, gastric, lung, melanoma, neuroblastoma, ovarian, pancreatic, prostate and renal cell cancer lines. PTC299 as a monotherapy significantly reduced VEGF concentrations in tumors and plasma, reduced tumor blood vessel density, and substantially impeded tumor progression.
PTC299 was designed to inhibit VEGF production in tumors by targeting the post-transcriptional control processes that regulate VEGF formation. Because PTC299 inhibits VEGF production, its action occurs at a different point in the VEGF pathway than therapies, such as Avastin or Sutent. PTC299 may be active both as a single agent or when used in combination with other anti-angiogenic agents or with chemotherapy agents for the treatment of cancers.
ABOUT THIS PAGE
60
PharmaCompass offers a list of Emvododstat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Emvododstat manufacturer or Emvododstat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Emvododstat manufacturer or Emvododstat supplier.
PharmaCompass also assists you with knowing the Emvododstat API Price utilized in the formulation of products. Emvododstat API Price is not always fixed or binding as the Emvododstat Price is obtained through a variety of data sources. The Emvododstat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Emvododstat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Emvododstat, including repackagers and relabelers. The FDA regulates Emvododstat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Emvododstat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Emvododstat supplier is an individual or a company that provides Emvododstat active pharmaceutical ingredient (API) or Emvododstat finished formulations upon request. The Emvododstat suppliers may include Emvododstat API manufacturers, exporters, distributors and traders.
Emvododstat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Emvododstat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Emvododstat GMP manufacturer or Emvododstat GMP API supplier for your needs.
A Emvododstat CoA (Certificate of Analysis) is a formal document that attests to Emvododstat's compliance with Emvododstat specifications and serves as a tool for batch-level quality control.
Emvododstat CoA mostly includes findings from lab analyses of a specific batch. For each Emvododstat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Emvododstat may be tested according to a variety of international standards, such as European Pharmacopoeia (Emvododstat EP), Emvododstat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Emvododstat USP).